Anticoagulants, Antiplatelets, and Thrombolytics

Anticoagulants, Antiplatelets, and Thrombolytics : Methods and Protocols

Edited by 

List price: US$118.99

Currently unavailable

Add to wishlist

AbeBooks may have this title (opens in new window).

Try AbeBooks

Description

This collection of review articles highlights the latest development of antithrombotics and provides proven experimental methods for the further development of new and improved anticoagulants. Among the cutting-edge developments reviewed are the novel usage of low molecular weight heparins, such antithrombin agents as the hirudin, and such antiplatelet drugs as the GPIIb/IIIa inhibitors and ADP receptor antagonists. Additional innovations discussed include aspirin and clopidogrel, the expanded use of polytherapeutic approaches, antiproteases (factors IIa, Xa, and VIIa), tissue factor targeting, platelet receptor targeting, and antithrombin III modulation.show more

Product details

  • Hardback | 320 pages
  • 159 x 230.1 x 29.7mm | 771.12g
  • Humana Press Inc.
  • Totowa, NJ, United States
  • English
  • New.
  • 31 black & white illustrations
  • 1588290832
  • 9781588290830

Review quote

From the reviews: "This book contains a number of informative topics on the latest advances in the field. a ] Basic science is completed with clinical results. Very complete guidelines for treatment of deep thrombosis and pulmonary embolism ends the book. This recommendable book a ] provides a clinical audience with a complete update on a major field in medicine." (Michel Telerman, Acta Cardiologica, April, 2005)show more

Table of contents

Highlights of Latest Advances in Antithrombotics Shaker A. Mousa Antiplatelet, Anticoagulant, and Thrombolytic Drug Interactions Omer Iqbal and Shaker A. Mousa Evaluation of Platelet Antagonists in In Vitro Flow Models of Thrombosis Owen J. T. McCarty, James P. Abulencia, Shaker A. Mousa, and Konstantinos Konstantopoulos Heparin and Low Molecular Weight Heparin in Thrombosis, Cancer, and Inflammatory Diseases Shaker A. Mousa Are Low Molecular Weight Heparins the Same? Shaker A. Mousa Antithrombotic Drugs for the Treatment of Heparin-Induced Thrombocytopenia Walter P. Jeske and Jeanine M. Walenga Laboratory Methods for Heparin-Induced Thrombocytopenia Margaret Prechel, Walter P. Jeske, and Jeanine M. Walenga Factor Xa Inhibitors Jeanine M. Walenga, Walter P. Jeske, Debra Hoppensteadt, and Jawed Fareed Tissue Factor/VIIa in Thrombosis and Cancer Shaker A. Mousa Tissue Factor Pathway Inhibitor in Thrombosis and Beyond Shaker A. Mousa, Jawed Fareed, Omer Iqbal, and Brigitte Kaiser Cell Adhesion Molecules: Potential Therapeutic and Diagnostic Implications Shaker A. Mousa Development and Applications of Animal Models of Thrombosis Ronald J. Shebuski, Larry R. Bush, Alison Gagnon, Liguo Chi, and Robert J. Leadley, Jr. A Survey of Venous Thrombosis Models Walter P. Jeske, Omer Iqbal, Jawed Fareed, and Brigitte Kaiser Arixtra(R) (Fondaparinux Sodium) Shaker A. Mousa Oral Thrombin Inhibitor Ximelagatran Shaker A. Mousa Pharmacogenomics and Coagulation Disorders Omer Iqbal Guidelines for Diagnosis and Treatment of Deep Venous Thrombosis and Pulmonary Embolism Hikmat Abdel-Razeq, Mohamad Qari, Jorgen Kristensen, Hussein Alizeidah, Faisal Al-Sayegh, Mahmoud Marashi, Abdulaziz Alzeer, Omar Al-Amoudi, Hatem Qutub, Abdel-Aziz Al-Humiadi, Steen Husted, and Shaker A. Mousa on behalf of the GCC Thrombosis Study Group Indexshow more